In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This...
Read More
In a nutshell This study examined the association between long-term use of three different tyrosine kinase inhibitors (TKIs) and the occurrence of vascular (blood vessel) adverse events (side effects; VAEs) in patients with chronic myeloid leukemia (CML). The data showed a possibly higher risk of developing VAEs when patients with CML were...
Read More
In a nutshell This study aimed to compare enasidenib (Idhifa) to current standard of care therapies for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoietic stem cell transplantation (HSCT). This study concluded that enasidenib significantly...
Read More
In a nutshell This study described the real-world effectiveness and safety of arsenic trioxide (ATO; Trisenox) combined with all-trans retinoic acid (ATRA; Vesanoid), without chemotherapy, in patients with newly diagnosed acute promyelocytic leukemia (APL). The authors concluded that a combination of ATO and ATRA showed good results for the...
Read More
In a nutshell The study aimed to investigate whether reduced-intensity conditioning (RIC) hemopoietic stem cell transplantation (HSCT) improves the outcomes of patients with chronic lymphocytic leukemia (CLL) with and without Richter's transformation (RT). This study concluded that this treatment may be suitable in early...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) combined with intensive chemotherapy in patients aged 65 or younger with acute myeloid leukemia (AML). This study concluded that venetoclax added to intensive chemotherapy was safe and effective in these...
Read More
In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...
Read More
In a nutshell This study aimed to determine the long-term outcomes and risk factors after allogeneic stem cell transplantation (allo-SCT) for patients with advanced phase chronic myeloid leukemia (CML). This study concluded that allo-SCT improved the outcomes of these patients, particularly in those with donors younger than 36...
Read More
In a nutshell This study compared acalabrutinib (Calquence) and ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL). The data showed that both drugs had similar effectiveness while acalabrutinib showed fewer cardiovascular side effects compared to ibrutinib. Some background Chronic lymphocytic...
Read More
In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...
Read More
In a nutshell The study aimed to investigate antibody responses in patients with chronic lymphocytic leukemia (CLL) after first and second Covid-19 vaccinations. This study concluded that antibody responses of these patients are lower than that of healthy people. Some background B-cell chronic lymphocytic leukemia (CLL) is...
Read More
In a nutshell This study evaluated the effectiveness of CPX-351 (Vyxeos; daunorubicin, cytarabine) versus standard chemotherapy for older patients with high-risk acute myeloid leukemia (AML). This study found that CPX-351 improved long-term outcomes for these patients. Some background AML is a cancer of the blood and bone marrow. AML can also...
Read More
